Mind Cure Comments on Recent Promotional Activity prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
Celebrated neurologist, psychiatrist and plant-medicine expert Dr. Dan Engle brings years of understanding of psychedelic medicine into research with Mind Cure.
VANCOUVER, BC, Feb. 17, 2021 /PRNewswire/ - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ( Mind Cure or the Company ) is pleased to announce the engagement of Dr. Dan Engle as Mind Cure s Primary Investigator Consultant. Dr. Engle is Board Certified in Psychiatry and Neurology, with a clinical practice that combines functional medicine, integrative psychiatry, neuro-cognitive restoration. He is celebrated for contribution to understanding of traumatic brain injury and concussion recovery with his book
Rise In Consumer Acceptance of Psychedelic Drug Therapies Is Quickly Increasing
Financialnewsmedia.com News Commentary
Share this article
Share this article
PALM BEACH, Fla., Feb. 17, 2021 /PRNewswire/ Psychedelics are making their way out of the counterculture and back into the mainstream, with research and media interest in the mind-altering substances growing substantially. Some have even called psychedelics psychiatry s brave new world. The revitalization of psychedelics has occurred alongside a shift away from the research and development of traditional psychiatric medications by leading pharmaceutical companies. A report from Data Bridge Market Research reported that the global psychedelic drugs market is rising gradually with a healthy CAGR in the forecast period of 2019-2026. Growing prevalence of depression worldwide and increase in special designation from the regulatory authorities to the company to expedite the development process are the key factors for market g
Mind Cure Closes $18M Raise
Mind Cure Health Inc. (CSE:MCUR) recently announced the closing of a CA$23 Million ($18.1 million) offering.
The company issued approximately 38 million units, consisting of one share and one half of a share purchase warrant, at CA$0.60 per unit.
The proceeds will be used to finance product research and development, advance the company’s technological capabilities, marketing expenditures and product awareness, as well as for working capital.
So far, Mind Cure has raised almost CA$31 million ($24.4 million) to date. The company’s operations are divided between five spheres, which include:
A line of non-psychedelic supplements using functional mushroom formulations that are already available to consumers.
Financial News Media | Rise In Consumer Acceptance of Psychedelic Drug Therapies Is Quickly Increasing financialnewsmedia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialnewsmedia.com Daily Mail and Mail on Sunday newspapers.